VolitionRx Limited filed a Form 8-K on November 12, 2026, disclosing that Chief Executive Officer and President Cameron Reynolds agreed to an additional temporary reduction in his annual base salary, effective November 1, 2026, as part of the company's cost reduction measures.
Key Highlights
- Further salary cut effective November 1, 2026: Cameron Reynolds agreed to reduce his annual base salary from $355,456 to $236,970.50, with no additional equity compensation for the reduction.
- Prior reduction already in place: As of February 1, 2026, Reynolds had already accepted a 25% cut from $473,941 to $355,456, in exchange for 24,300 restricted stock units vesting on February 26, 2027.
- No set end date: The further temporary reduction remains in effect until the Compensation Committee, in its sole discretion, determines that the full contractual salary should be reinstated, in whole or in part.
- Reinstatement trigger: According to the filing, the Compensation Committee may make a reinstatement determination "following the signing of a significant licensing agreement or another commercial outcome" that it judges secures the company's financial stability.
- Key protections retained: Termination-related payments, notice pay, severance, death or disability payments, and pension allowance will continue to be calculated by reference to Reynolds' full contractual annual base salary of $473,941.
- Reinstatement is not retroactive: Any reinstatement takes effect only from the date specified by the Compensation Committee and "will not apply retrospectively," according to the filing.
Reynolds Employment Agreement Amended for Second Time in 2026
According to the Form 8-K filed with the SEC on November 12, 2026, Singapore Volition Pte. Limited, a wholly-owned subsidiary of NYSE American:VNRX VolitionRx Limited, and Cameron Reynolds entered into a variation letter dated November 10, 2026, amending the existing employment agreement originally dated March 13, 2023. The amendment reflects what the filing describes as part of "the Company's overall cost reduction measures."
The filing reports that Reynolds had already accepted a 25% salary reduction effective February 1, 2026, bringing his annual base salary from $473,941 down to $355,456 for a 12-month period running through January 31, 2027. In exchange for that earlier reduction, Reynolds received a grant of 24,300 restricted stock units, earned in equal monthly installments, with full vesting contingent on continuous service through February 26, 2027. The November 10, 2026 amendment goes further: effective November 1, 2026, Reynolds agreed to lower his salary again, from $355,456 to $236,970.50, this time without any additional equity compensation.
The filing specifies that certain contractual protections for Reynolds remain intact despite the salary reduction. Notice pay, severance, death or disability payments, and other termination-related entitlements will continue to be computed against the full contractual annual base salary of $473,941. The pension allowance will similarly be calculated by reference to that full figure. The filing notes that all other terms of the Reynolds Employment Agreement "remain unchanged and in full force and effect." The full text of the amended agreement is expected to be filed as an exhibit to the company's Quarterly Report on Form 10-Q for the period ended September 30, 2026.
What Was Disclosed
VolitionRx disclosed a second temporary salary reduction for CEO Cameron Reynolds in 2026, cutting his pay from $355,456 to $236,970.50 effective November 1, 2026, with no additional equity grant. Reinstatement is at the sole discretion of the Compensation Committee and will not be retroactive.




Please wait processing your request...